August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...
TITUSVILLE, N.J., Nov. 19, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic ...
Schizophrenia is a mental health disorder that causes changes to the way a person thinks, acts, and behaves. People with schizophrenia may have hallucinations, delusions, disorganized behavior, and ...
Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study published ...
Janssen R&D announced that the Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to treat ...
(RTTNews) - Janssen Pharmaceutical, Inc., wholly-owned by Johnson & Johnson (JNJ), announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results